The diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019, and is expected to reach $ 7,054.4million by 2027, with a CAGR of 5.1%, during the forecast period.
DTP refers to diphtheria, tetanus, and pertussis. Vaccines used for DTP are immunization drugs initially administered at the age of two to produce acquired immunity against DTP (Diphtheria, Tetanus, and Pertussis). Since 1974, DTP vaccines have been part of the Expanded Programme of Immunisation (EPI) vaccination schedule. DTP as a standalone vaccine has been declined substantially. Rise in demand for tetravalent and subsequently pentavalent combination vaccines has principally contributed to this shift. The increased combination product demand has largely been led by GAVI (Global Alliance for Vaccines and Immunizations) funding for other DTP-containing vaccines.
With high DTP vaccination rates of 86%, globally in 2018, the incidences of diphtheria and tetanus have been well controlled. However, the disease continues to cause illness globally. According to the Centre for Disease control and prevention, in 2016, reported about 7,100 cases of diphtheria and 1248 cases of pertussis to the World Health Organization globally. Owing to the rise in number of cases during late spring and early summer further drives the DTP vaccine market demand for DTP vaccines, especially for advanced vaccines.
Growth in government and non-government initiatives for vaccine development, coupled with surge in awareness among people regarding these vaccines boosts the DTP vaccine market growth. However, high cost of vaccine development and inadequate access to vaccines in under developed countries restrict the market growth. Moreover, emerging markets offer lucrative opportunities for the key market players.
Product segment review
On the basis of product, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in demand for DTaP vaccines and growth in adoption of pertussis vaccines around the globe drives the growth of this segment. The WHO suggests that inoculation helps in preventing 2 to 3 million deaths every year against tetanus, diphtheria, whooping cough, and measles. Only few cases of respiratory diphtheria were reported by the CDC from 1996 to 2016, post the introduction of vaccines. However, inadequately vaccinated or unvaccinated travelers are at more risk of acquiring infections. Thus, governments globally have made it mandatory to immunize travelers visiting countries with infectious diseases to prevent further spread of infectious agents. Likewise, as per the stats provided in 2015 by the WHO, approximately 85% infants received three doses of DTaP vaccine across the globe. Rise in adoption of pertussis vaccine, high birth rates, growth in initiatives taken by governments, and insurance and reimbursement scenarios in different countries provided by governments drive the DTaP vaccines market growth globally.
By Product
DTaP holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.
Age Group segment review
On the basis of age group, the DTP vaccines market is segmented into pediatrics vaccines and adult vaccines. Vaccines for adults are likely to show high growth potential due to rise in incidences of infectious diseases among adults. In addition, growth in research and development and strong product pipeline is also likely to increase the growth of the segment during the forecast period. However, the pediatrics segment dominated the market due to high demand of DTP vaccine among infants. The potential size of pediatrics vaccines segment is based on the facts that birthrate is increasing globally, which boosts the doses for pediatrics vaccines and as per the WHO norms infants worldwide have to receive 3 doses of DTP vaccine necessarily to cope with the life threatening diseases.
By Age Group
Pediatric segment is projected as one of the most lucrative segments.
Region segment review
By region, the diphtheria, pertussis, and tetanus (DTP) vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2019, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. Asia-Pacific is expected to witness highest growth rate for the DTP vaccine market throughout the forecast period. Increase in demand for DTP vaccines, growth in awareness of newer technologies and rise in population awareness are prime factors that supplement the adoption of DTP vaccine.
By End User
Hospitals holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.
The report provides a comprehensive analysis of the key players operating in the global DTP Vaccine market, namely AJ Vaccines, Bionet-Asia, GlaxoSmithKline plc (GSK), Johnson & Johnson, Massbiologics, Meiji Holdings Co., Ltd. (KM biologics co., Ltd.), Merck & Co., Inc., Panacea Biotec Ltd., Sanofi, and Serum Institute of India Pvt. Ltd.
By Region
Asia-Pacific region would exhibit the highest CAGR of 6.1% during 2020-2027.
Key Benefits For Stakeholders
This report provides a detailed quantitative analysis of the current DTP Vaccine market trends and forecast estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.
An in-depth DTP vaccine market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
Region-wise and country-wise market conditions are comprehensively analyzed in this report.
The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2027, in terms of value.
An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the DTP Vaccine market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global DTP Vaccine market.
Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Age Group |
|
 By End User |
|
 By Region |
|
 Key Market Players | MASSBIOLOGICS, BIONET-ASIA, GLAXOSMITHKLINE PLC (GSK), JOHNSON & JOHNSON, SERUM INSTITUTE OF INDIA PVT. LTD, AJ VACCINES, PANACEA BIOTEC LTD., SANOFI, MEIJI HOLDINGS CO., LTD. (KM BIOLOGICS CO., LTD.), MERCK & CO., INC. |
Analyst Review
The global diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% during the forecast period.
Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough). A 0.5 mL booster should be given intramuscularly to children between the ages of 4 and 6.
In May, 2012, the WHO launched the ‘Global Vaccine Action Plan (GVAP),’ which was authorized by 194 member states of the World Health Assembly. This plan aims to strengthen standard immunization to check the transmission of communicable diseases through periodic assessments and evaluate the achieved progress, which is measured in terms of national vaccination coverage target goals, which are constructively met. In addition, rise in involvement of government and non-government organizations in this field is expected to provide an impactful boost to the market growth.
Improvements in healthcare infrastructure, growth in vaccination awareness, and rise in incidences of preventable diseases drive the growth of the global DTP vaccines market. However, a number of limitations are associated with DTP vaccines such as lack of medical aids in underdeveloped regions and high cost investments in vaccine manufacturing, which restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 5.1% from 2020 to 2027. On the contrary, emerging markets are anticipated to offer significant growth opportunities for market players in the future
The global DTP vaccine market is segmented into product type, age group, end user, and region. By product, it is divided into DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is classified into adult and pediatric. Further, on the basis of end user, it is bifurcated into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits For Stakeholders
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global DTP vaccine market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key Market Segments
By Product Type
- DTaP
- TD
- Tdap
By Age Group
- Adult
- Pediatric
By End User
- Hospitals
- Clinics
- Vaccination Centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Rest of LAMEA
The total value of Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market was $4,758.8 million in 2019.
The forecast period in the report is from 2020-2027.
The market value of Diphtheria, Tetanus, and Pertussis (DTP) Vaccine in 2020 was $4,993.04 million.
The base year calculated is 2019 in the report.
As per the study GlaxoSmithKline plc (GSK) and Sanofi are the top market share holders in global Diphtheria, Tetanus, and Pertussis (DTP) Vaccine market
Rise in initiatives by pharma companies to enhance vaccine R&Das well as rise in healthcare expenditure are expected to drive the market growth during the forecast period.
The growth % of the Diphtheria, Tetanus, and Pertussis (DTP) Vaccine is 5.1%.
DTaP vaccines segment holds the maximum market share.
DTaP and TD vaccines segment is are the key matured markets growing in the Diphtheria, Tetanus, and Pertussis (DTP) Vaccine market
Rise in adoption of pertussis vaccine, high birth rates, growth in initiatives taken by government, and insurance and reimbursement scenarios in different countries provided by governments drive the DTaP vaccines market growth globally
Loading Table Of Content...
